Cargando…

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.

Detalles Bibliográficos
Autores principales:	Kalac, M., Tam, C., Goldfinger, M., Xiao, Z., Rajeeve, S., Montanari, F., Kanakry, J., O’Connor, O., Marchi, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431246/ http://dx.doi.org/10.1097/01.HS9.0000847644.74540.4d

Ejemplares similares

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma
por: Kalac, Matko, et al.
Publicado: (2023)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
por: Irlé, Claudius, et al.
Publicado: (2016)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
por: Foss, Francine, et al.
Publicado: (2016)

Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin
por: Costello, Collin M., et al.
Publicado: (2019)

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression
por: Sato, Shuku, et al.
Publicado: (2020)

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
por: Ruan, Jia, et al.
Publicado: (2023)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

Romidepsin Used as Monotherapy in Sequence with Allogeneic Stem Cell Transplant in a Patient with Peripheral T-Cell Lymphoma
por: Finn, Nicholas, et al.
Publicado: (2014)

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
por: Coiffier, Bertrand, et al.
Publicado: (2014)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
por: Pro, Barbara, et al.
Publicado: (2016)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2016)

Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma
por: Poligone, Brian, et al.
Publicado: (2011)

Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma
por: Jothishankar, Balaji, et al.
Publicado: (2020)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Pellegrini, Cinzia, et al.
Publicado: (2016)

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2017)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

1195. "The Economic Impact of Antimicrobial Use for Surgical Prophylaxis: A Prospective Study
por: Gnanamani, James, et al.
Publicado: (2023)

Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
por: Kim, Ellen J., et al.
Publicado: (2015)

Relief of intractable pruritus with romidepsin in patients with cutaneous T‐cell lymphoma: A series of four cases
por: Poligone, Brian, et al.
Publicado: (2019)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
por: Guo, Yuelu, et al.
Publicado: (2023)

R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
por: Safari, Maryam, et al.
Publicado: (2021)

The COX-2-1195AA Genotype Is Associated with Diffuse-Type Gastric Cancer in Korea
por: Shin, Woon Geon, et al.
Publicado: (2012)

EP1195: COVID-19 INFECTION AND BREAKTHROUGH INFECTION IN POST LIVER TRANSPLANT PATIENTS
por: Moein, Hamid-Reza, et al.
Publicado: (2022)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
por: Horwitz, S., et al.
Publicado: (2015)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Association of COX-2 Promoter Polymorphisms -765G/C and -1195A/G with Migraine
por: MOZAFFARI, Elahe, et al.
Publicado: (2016)

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017)

A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia
por: Hu, Rong-Hua, et al.
Publicado: (2022)

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
por: Cosenza, Maria, et al.
Publicado: (2016)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
por: Jo, Tatsuro, et al.
Publicado: (2020)

Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides
por: Lemchak, David. M., et al.
Publicado: (2016)

Complete Genome Sequence of Bifidobacterium dentium Strain JCM 1195(T), Isolated from Human Dental Caries
por: Toh, Hidehiro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7lu4ftl8pq87759ct56b6q9ajd